Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.66 EUR
Change Today +0.02 / 0.76%
Volume 259.0K
SRN On Other Exchanges
Symbol
Exchange
BrsaItaliana
Frankfurt
As of 11:30 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Open
€2.64
Previous Close
€2.64
Day High
€2.68
Day Low
€2.61
52 Week High
03/6/15 - €3.07
52 Week Low
10/15/14 - €1.63
Market Cap
1.3B
Average Volume 10 Days
487.1K
EPS TTM
€0.11
Shares Outstanding
478.7M
EX-Date
--
P/E TM
24.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A. develops, produces, and distributes medical devices for cardiac surgery and for the treatment of cardiac rhythm dysfunctions. It offers disposable biomedical devices and systems, including heart-lung machines; cardiopulmonary systems, such as oxygenators and custom packs; autotransfusion systems and disposables; perfusion tubing systems; cannulae; and endoscopic vessel harvesting systems for extracorporeal circulation during surgery. The company also provides mechanical heart valves, tissue heart valves, self-anchoring tissue heart valves, and annuloplasty rings to replace or repair dysfunctional heart valves or treat congenital diseases. In addition, it offers implantable devices, monitoring systems, and accessories to treat cardiac rhythm dysfunctions that comprise pacemakers, implantable defibrillators, systems to treat heart failure (CRT-D), programmers, electrodes, electrophysiology leads, and Holter monitors; and disposable medical devices for urology, urodynamics, heart surgery, and haemodialysis. The company sells its products worldwide primarily under the Sorin Biomedica, Dideco, Stöckert, Cobe Cardiovascular, Ela Medical, and Carbomedics brand names. Sorin S.p.A. was founded in 2004 and is headquartered in Milan, Italy.

3,900 Employees
Last Reported Date: 03/16/15
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €789.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2013.

sorin spa (SRN) Key Developments

Sorin Announces Encouraging Data from Aortic Stenosis Study

Sorin Group has announced new data demonstrating improved clinical outcomes after use of the next-generation Perceval sutureless aortic valves in European patients with severe aortic stenosis. The first set of findings, presented by Prof. Claudio Muneretto from University of Brescia Medical School, Italy, demonstrated significantly greater rates of short and mid-term survival among 991 patients with severe aortic stenosis and an intermediate-high risk profile (STS Score: 4-8%) after treatment with conventional surgery or sutureless valve replacement compared to Trans-Catheter Aortic Valve Replacements (TAVR). The second study "The rise of new technologies for aortic valve stenosis: a propensity-score analysis from two multicenter registries comparing sutureless and trans-catheter aortic valve replacement" presented by Dr. Augusto D'Onofrio showed that Perceval valves had better device success and a lower rate of mild paravalvular leakage (PVL) when compared to TAVR in patients with severe symptomatic aortic stenosis, and the third one, "First Large Cohort with a Sutureless Aortic Valve: The 1 Year Follow-Up of 628 Consecutive Patients from an International Multicenter Prospective Trial" presented by Prof. Theodor Fischlein, Nurnberg, confirmed the safety and effectiveness of the Perceval Sutureless aortic valve at 1 year in a prospective, non-randomized, multi-center study. Prof. Muneretto presented the results of an independently conducted 991-patient multicenter propensity-score analysis based on the therapeutical strategy: sutureless AVR with Perceval, TAVR and conventional surgery (sAVR). The 30-day mortality rate was 5.8% among patients treated with sutureless valve replacement compared to 9.8% for those who received TAVR and to 3.4% for sAVR. Overall survival rates at 24 months were 94.9±2.1% in the sutureless valve group, 79.5±4.3% in the TAVR group and 91.3±2.4% in the sAVR group. Sutureless valves were also associated with lower rates of postoperative complications, including peripheral vascular complications at 30 days (0% in sutureless and sAVR groups compared to 9.8% in TAVR group) and higher rates of patients who were free from major adverse cardiac and cerebrovascular events and periprostetic regurgitation at 24 months (96.0% in the sutureless valve group compared to 77.1% in the TAVR group and 92.6% in the sAVR group). "These results demonstrate that for intermediate-high risk patients, Perceval valve is associated with lower rates of mortality and postoperative complications compared to TAVR," said Professor Claudio Muneretto, M.D.,Ph.D., Director of the Department of Cardiac Surgery at the University of Brescia Medical School in Brescia, Italy. Dr. Augusto D'Onofrio, from University of Padua, Italy, presented findings from a separate propensity-score analysis of two multicenter registries including 2,175 patients (292 underwent isolated AVR with Perceval and 1,885 TAVR). In the overall cohort before matching, mild PVL was 1.7% in the sutureless cohort versus 31.8% in the TAVR patients. After propensity matching, TAVR patients were more likely to show less device success and more postoperative PVL, even though this was not evident in transapical TAVR. Prof. Fischlein, from the Department of Cardiac Surgery, Klinikum Nurnberg, Paracelsus Medical University, Nuremberg, Germany, presented the 1 year results of the CAVALIER trial. This prospective, multi-center study was conducted in a cohort of 628 implanted patients to demonstrate the safety and effectiveness of the Perceval Sutureless aortic valve. The results showed that, despite the fairly old population (40% octogenarians) with an intermediate patient risk profile (STS Score 7.2%), the overall clinical outcomes at 1 year are very promising, with a low rate of cardiac mortality, stroke, major paravalvular leak, valve explants, and no incidents of valve migration, valve thrombosis, or structural valve deterioration. The patient clinical status improved and remained stable throughout follow up.

Sorin and Cyberonics Announce Executive Leadership Team for the New Company Upon Close of Merger

Sorin S.p. A and Cyberonics Inc. announced the executive leadership team for the new company effective at the close of the proposed merger. André-Michel Ballester, Sorin’s Chief Executive Officer, will serve as the new company’s Chief Executive Officer, and Dan Moore, Cyberonics’ Chief Executive Officer, will be the non-executive Chairman. The new company will be organized into three business units and an Intercontinental group, with the following leaders: Michel Darnaud, Sorin’s President, Cardiac Surgery, will lead the Cardiac Surgery business unit. Stefano Di Lullo, Sorin’s President, Cardiac Rhythm Management, will lead the Cardiac Rhythm Management business unit. Rohan Hoare, Cyberonics’ Chief Operating Officer, will lead the Neuromodulation business unit. Jacques Gutedel, Sorin’s Vice President, Intercontinental, will head the Intercontinental group. The new company’s Executive Leadership Team will also include the following functional leaders: Ed Andrle, Sorin’s Vice President, Strategy & Business Development, will manage Strategy, Business Development and New Ventures /Emerging Therapies. Brian Sheridan, Sorin’s General Counsel, will serve as General Counsel for the combined organization. Pritpal Shinmar, Sorin’s Vice President, Market Access, will be responsible for the Global Market Access function. David Wise, Cyberonics’ Chief Administrative Officer, will lead the Human Resources and the Information Technology functions. Sorin and Cyberonics have initiated a search for the Chief Financial Officer position of the combined company and expect to name the selected candidate before closing. Greg Browne, Cyberonics’ Chief Financial Officer, will serve as interim Chief Financial Officer for the new company, should the position not be filled prior to closing, and plans to retire in 2016. Demetrio Mauro, Sorin’s Chief Financial Officer, will lead the overall integration as Chief Integration Officer to ensure the new company is fully operational on day one following closing. The role also calls for significant planning for the post-closing period, including achievement of previously announced synergies. Until the closing of the transaction, the respective companies will continue to operate under current leadership structures and as two separate companies. As previously announced, the transaction is expected to be completed by the end of the third calendar quarter of 2015 and is subject to approval by both Sorin and Cyberonics shareholders, the receipt of required regulatory clearances, and other customary closing conditions.

Sorin S.p.A. and Cyberonics Inc. Announce Formation of New Company

Sorin S.p.A. and Cyberonics Inc. announced the Executive Leadership Team for the new company effective at the close of the proposed merger. The new company will be organized into three business units and an Intercontinental group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.66 EUR +0.02

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $130.88 USD -0.94
InspireMD Inc $0.24 USD +0.03
Smith & Nephew PLC 1,134 GBp -6.00
Stentys €6.03 EUR -0.07
Zimmer Holdings Inc $113.77 USD -0.69
View Industry Companies
 

Industry Analysis

SRN

Industry Average

Valuation SRN Industry Range
Price/Earnings 32.0x
Price/Sales 1.7x
Price/Book 2.0x
Price/Cash Flow 31.1x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit www.sorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.